Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis by Longinetti, E. et al.
  
 
 
 
 
 
 
 
 
 
 
 
This is an author produced version of a paper not yet 
published by a journal. This version is the preprint (not peer-
reviewed) and does not include the final publisher proof-
corrections or journal pagination. 
 
Neurodegenerative and psychiatric diseases among 
families with amyotrophic lateral sclerosis 
 
Longinetti, E.; Mariosa, D.; Larsson, H.; Ye, W.; Ingre, 
C.; Almqvist, C.; Lichtenstein, P.; Piehl, F.; Fang, F. 
 
Access to the published version may require subscription. 
  
 
 
 
Neurodegenerative and psychiatric diseases among families with amyotrophic lateral 
sclerosis  
 
Authors: Elisa Longinetti, MSc, Daniela Mariosa, MSc, Henrik Larsson, PhD, Weimin Ye, MD, PhD, 
Caroline Ingre, MD, PhD, Catarina Almqvist, MD, PhD, Paul Lichtenstein, PhD, Fredrik Piehl, MD, PhD, 
Fang Fang, MD, PhD
 
Elisa Longinetti, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet 
Daniela Mariosa, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet 
Henrik Larsson, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, and 
Department of Medical Sciences, Örebro University 
Weimin Ye, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet 
Caroline Ingre, Department of Clinical Neuroscience, Karolinska Institutet 
Catarina Almqvist, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, and Astrid 
Lindgren Children’s Hospital, Lung and Allergy Unit, Karolinska University Hospital 
Paul Lichtenstein, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet 
Fredrik Piehl, Department of Clinical Neuroscience, Karolinska Institutet 
Fang Fang, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet 
 
Title character count: 93 
Number of references: 35 
Number of tables: 4 
Word count abstract: 250 
Word count paper: 2994 
  
 
 
 
 
Supplemental data: International Classification of Diseases (ICD) codes used to identify amyotrophic lateral 
sclerosis (ALS), neurodegenerative diseases, and psychiatric disorders in the Swedish Patient Register, 
Table e-1; Adjusted associations for age, sex, and county of birth among patients with amyotrophic lateral 
sclerosis (ALS) and their matched ALS-free controls show a higher-than-expected occurrence of 
neurodegenerative and psychiatric diseases after ALS diagnosis (hazard ratios); follow-up stopped at 69 
years, Table e-2; Adjusted associations for age, sex, and county of birth among relatives of patients with 
amyotrophic lateral sclerosis (ALS) and relatives of their matched ALS-free controls do not show clear 
temporal pattern in the associations of ALS with  neurodegenerative and psychiatric diseases, Table e-3; 
Adjusted associations for age, sex, and county of birth among patients with amyotrophic lateral sclerosis 
(ALS) and their relatives, compared to ALS-free individuals, show a higher-than-expected occurrence of 
neurodegenerative and psychiatric diseases among ALS patients, of neurodegenerative diseases among 
siblings of ALS patients, and of psychiatric disorders among children of ALS patients, both before (odds 
ratios) and after (hazard ratios) ALS diagnosis; separate analysis for males, Table e-4; Adjusted associations 
for age, sex, and county of birth among patients with amyotrophic lateral sclerosis (ALS) and their relatives, 
compared to ALS-free individuals, show a higher-than-expected occurrence of neurodegenerative and 
psychiatric diseases among ALS patients, and of neurodegenerative diseases among siblings of ALS 
patients, both before (odds ratios) and after (hazard ratios) ALS diagnosis; separate analysis for females, 
Table e-5; Adjusted associations for age, sex, and county of birth among patients with amyotrophic lateral 
sclerosis (ALS) and their relatives, compared to ALS-free individuals, show a higher-than-expected 
occurrence of neurodegenerative and psychiatric diseases among ALS patients, and of psychiatric disorders 
among children of ALS patients, both before (odds ratios) and after (hazard ratios) ALS diagnosis; separate 
analysis for individuals ≤55 years, Table e-6; Adjusted associations for age, sex, and county of birth among 
patients with amyotrophic lateral sclerosis (ALS) and their relatives, compared to ALS-free individuals, 
show a higher-than-expected occurrence of neurodegenerative and psychiatric diseases among ALS patients, 
  
 
 
 
and of neurodegenerative diseases among siblings of ALS patients, both before (odds ratios) and after 
(hazard ratios) ALS diagnosis; separate analyses for individuals ≥56 years, Table e-7; Adjusted associations 
for age, sex, and county of birth among patients with familial amyotrophic lateral sclerosis (ALS) and their 
matched ALS-free controls show a higher-than-expected occurrence of neurodegenerative and psychiatric 
diseases among familial ALS patients, both before (odds ratios) and after (hazard ratios) ALS diagnosis, 
Table e-8; Adjusted associations for age, sex, and county of birth among patients with amyotrophic lateral 
sclerosis (ALS) and their matched ALS-free controls show a higher-than-expected occurrence of 
neurodegenerative diseases among ALS patients, even after excluding frontotemporal dementia from the 
definition of neurodegenerative diseases, Table e-9.  
Corresponding author:  
Elisa Longinetti 
Department of Medical Epidemiology and Biostatistics 
Karolinska Institutet, SE-17177 
Stockholm, Sweden 
Phone +46(0)8-52482731 
Fax: +46 (0)8-31 11 01 
elisa.longinetti@ki.se 
 
Elisa Longinetti – elisa.longinetti@ki.se 
Daniela Mariosa – daniela.mariosa@ki.se  
Henrik Larsson – henrik.larsson@ki.se 
Weimin Ye – weimin.ye@ki.se 
Caroline Ingre – caroline.ingre@ki.se 
Catarina Almqvist – catarina.almqvist@ki.se  
Paul Lichtenstein – paul.lichtenstein@ki.se  
  
 
 
 
Fredrik Piehl – fredrik.piehl@ki.se 
Fang Fang – fang.fang@ki.se 
 
Statistical Analysis conducted by: Elisa Longinetti, MSc, Department of Medical Epidemiology and 
Biostatistics, Karolinska Institutet 
Search Terms: All Cognitive Disorders/ Dementia, All Psychiatric Disorders, Amyotrophic lateral sclerosis, 
All Epidemiology 
Author Contributions: 
Elisa Longinetti, study concept and design, data analysis and interpretation, first drafting of the manuscript, 
critical revision of the manuscript for important intellectual content. 
Daniela Mariosa, study concept and design, data analysis and interpretation, critical revision of the 
manuscript for important intellectual content. 
Henrik Larsson, critical revision of the manuscript for important intellectual content 
Weimin Ye, critical revision of the manuscript for important intellectual content 
Caroline Ingre, critical revision of the manuscript for important intellectual content 
Catarina Almqvist, critical revision of the manuscript for important intellectual content 
Paul Lichtenstein, critical revision of the manuscript for important intellectual content 
Fredrik Piehl, study concept and design, data analysis and interpretation, critical revision of the manuscript 
for important intellectual content 
Fang Fang, study concept and design, data analysis and interpretation, critical revision of the manuscript for 
important intellectual content, study supervision 
 
Author Disclosures:  
Ms. Elisa Longinetti reports no disclosures 
  
 
 
 
Ms. Daniela Mariosa reports no disclosures  
Dr. Henrik Larsson has served as speaker for Eli-Lilly and Shire and received a research grant from Shire. 
Dr. Weimin Ye reports no disclosures 
Dr. Caroline Ingre reports no disclosures 
Dr. Catarina Almqvist reports no disclosures  
Dr. Paul Lichtenstein reports no disclosures  
Dr. Fredrik Piehl reports no disclosures 
Dr. Fang Fang reports no disclosures 
 
 
Study funded by the Swedish Research Council (grant no. 2015-03170), the Swedish Initiative for Research 
on Microdata in the Social and Medical Sciences (SIMSAM) (framework grant no. 340-2013-5867), the 
Swedish Society of Medical Research, and the Karolinska Institutet (Partial Finance for PhD Student, Senior 
Researcher Award, and Strategic Research Program in Epidemiology). This study was also partially 
supported by EU Joint Programme – Neurodegenerative Disease Research (JPND).  
 
 
 
 
 
 
 
Abstract  
Objective: To estimate risks of neurodegenerative and psychiatric diseases among patients with 
amyotrophic lateral sclerosis (ALS) and their families. 
  
 
 
 
Methods: We conducted a register-based nested case-control study during 1990-2013 in Sweden to assess 
whether ALS patients had higher risks of other neurodegenerative and psychiatric diseases before diagnosis. 
We included 3,648 ALS patients and 36,480 age-, sex-, and county-of-birth matched population controls. 
We further conducted a follow-up study of the cases and controls to assess the risks of other 
neurodegenerative and psychiatric diseases after ALS diagnosis. To assess the potential contribution of 
familial factors, we conducted similar studies for the relatives of ALS patients and their controls.  
Results: Individuals with previous neurodegenerative or psychiatric diseases had a 49% increased risk of 
ALS (odds ratio=1.49, 95% confidence interval=1.35-1.66), compared to individuals without these diseases. 
After diagnosis, ALS patients had increased risks of other neurodegenerative or psychiatric diseases (hazard 
ratio=2.90, 95% confidence interval=2.46-3.43), compared to individuals without ALS. The strongest 
associations were noted for frontotemporal dementia, Parkinson’s disease, other dementia, Alzheimer’s 
disease, neurotic disorders, depression, stress-related disorders, and drug abuse/dependence.  First-degree 
relatives of ALS patients had higher risk of neurodegenerative diseases, whereas only children of ALS 
patients had higher risk of psychiatric disorders, compared to relatives of the controls.  
Conclusions: Familial aggregation of ALS and other neurodegenerative diseases implies a shared 
etiopathogenesis among all neurodegenerative diseases. The increased risk of psychiatric disorders among 
ALS patients and their children might be attributable to non-motor symptoms of ALS and severe stress 
response toward the diagnosis. 
 
Introduction 
Amyotrophic lateral sclerosis (ALS) overlaps clinically and pathologically with other neurodegenerative 
diseases 
1-5
. Family members of ALS patients have also been reported to have increased risks of dementia 
and Parkinson’s disease (PD) 6, 7, further supporting the hypothesis of a shared etiopathogenesis between 
ALS and other neurodegenerative diseases 
6, 8, 9
. Increased risk of psychiatric disorders has been suggested 
  
 
 
 
among patients with ALS in some but not all studies 
10-12
 and little is known for the risk of psychiatric 
disorders among families of ALS patients 
6
. We performed therefore a nationwide register-based study in 
Sweden to estimate the risk of neurodegenerative and psychiatric diseases among patients with ALS and 
their family members.  
Methods  
Study base 
The Swedish Multi-Generation Register includes information on familial links for all individuals born in 
Sweden since 1932 
13
. We defined our study population as all individuals included in this register that were 
born in Sweden during 1932-2013 (N=8,575,515). Using the unique personal identification numbers 
assigned to all Swedish residents 
14
, we followed the study population from January 1
st
 1990 or date of birth, 
whichever came later, until date of ALS diagnosis, death, emigration out of Sweden, or December 31
st
 2013, 
whichever came first, through cross-linkages to the Swedish Patient Register, Causes of Death Register, and 
Migration Register. The Patient Register collects data on hospital discharge records in Sweden since 1964 
and has a nationwide coverage since 1987 
14
. Since 2001 it also collects data on hospital-based outpatient 
specialist care. Diagnoses from each hospital visit are classified according to the Swedish Revisions of the 
International Classification of Disease (ICD) codes (ICD-7 before 1969, ICD-8 during 1969-1986, ICD-9 
during 1987-1996, and ICD-10 from 1997). We identified all newly diagnosed ALS cases during follow-up 
through the Patient Register, indicated by a hospital visit concerning ALS, and defined the first hospital visit 
as ALS diagnosis date. We ascertained date of death from the Causes of Death Register and date of first 
emigration out of Sweden from the Migration Register. We excluded individuals that had been diagnosed 
with ALS (N=662), died (N=120,612), or emigrated out of Sweden (N=186,670) before the beginning of 
follow-up, leaving 8,269,319 (96%) participants in the study base.  
  
 
 
 
Nested case-control study I 
We conducted a nested case-control study within the above study base to assess the association of previous 
neurodegenerative and psychiatric diseases with the subsequent ALS risk. We defined cases as individuals 
diagnosed with ALS during follow-up (ICD-9 code 335C, ICD-10 code G12.2; N=3,648). For each index 
case we randomly selected 10 controls from the study base, by incidence density sampling, and individually 
matched the controls to the cases by year and month of birth, sex, and county of birth (N=36,480). Eligible 
controls had to be alive, living in Sweden, and ALS-free, at the time of the diagnosis of the index case. 
Nested case-control study II 
To investigate whether relatives of ALS patients had increased risk of neurodegenerative and psychiatric 
diseases before the diagnosis of the proband ALS patient, we conducted a second nested case-control study, 
including relatives of the index ALS patients and their matched controls. We identified parents, full siblings, 
half-siblings, and children of the index cases and controls from the Multi-Generation Register and used them 
as cases and controls for the nested case-control study II. We used the index dates of the index cases and 
controls as the index dates for the respective relatives. We excluded from the analyses relatives that had died 
or emigrated out of Sweden before the index date.  
Follow-up studies 
To examine the relative risks of neurodegenerative and psychiatric diseases after ALS diagnosis we 
prospectively followed the above nested case-control studies from the index date. In these analyses, we 
included only individuals without any neurodegenerative or psychiatric diseases diagnosed prior to the index 
dates, leading to 3,169 ALS cases and 33,110 controls in the follow-up study of nested case-control study I, 
and 13,313 relatives of ALS patients and 130,321 relatives of the index controls in the follow-up study of 
the nested case-control study II. We followed all individuals from the index date to the date of first diagnosis 
of neurodegenerative or psychiatric diseases, death, emigration out of Sweden, or December 31
st
 2013, 
whichever came first.  
  
 
 
 
Ascertainment of neurodegenerative and psychiatric diseases 
Neurodegenerative diseases examined in this study included frontotemporal dementia (FTD), Alzheimer's 
disease (AD), other or unspecific dementia, and PD, because we had previously reported risk of ALS among 
relatives of ALS patients 
15
. Psychiatric disorders examined in this study included schizophrenia, bipolar 
disorder, depression, neurotic disorders, stress-related disorders, alcohol abuse/dependence, and drug 
abuse/dependence. We defined a diagnosis of these diseases through a hospital visit concerning the specific 
disease as recorded in the Patient Register and used the date of first hospital visit as the diagnosis date. 
Because the Patient Register achieved good coverage on psychiatric diagnoses in 1973 
16
, we ascertained the 
diagnoses of neurodegenerative and psychiatric diseases from 1973 until the index date for the nested case-
control studies and from the index date until the end of follow-up for the follow-up studies. A list of the 
corresponding ICD codes is provided in Table e-1. 
Statistical analysis 
In the nested-case control studies, we estimated odds ratios (ORs) of ALS (or becoming a relative of an ALS 
patient) and corresponding 95% confidence intervals (CIs) using conditional logistic regression, as measures 
of the associations between previous neurodegenerative or psychiatric diseases and the subsequent ALS risk. 
Because cases and controls were individually matched by year and month of birth, sex, and county of birth 
in the nested case-control study I, these variables were automatically adjusted for in the analyses. In the 
nested case-control study II, we adjusted all models for year and month of birth, sex, and county of birth of 
the relatives as well as of the proband individuals. 
 
In the follow-up studies, we fitted Cox proportional hazard regression to derive hazard ratios (HRs) for the 
future risk of neurodegenerative and psychiatric diseases, comparing ALS patients to their controls and the 
relatives of ALS patients to the relatives of the index controls. We used attained age as the underlying time 
scale and further adjusted all models for sex and county of birth. We tested the assumption of proportional 
hazards using Schoenfeld residuals. 
  
 
 
 
 
In addition to the overall analyses, we separately analyzed specific time windows in the nested case-control 
studies and the follow-up studies (≥6 years, 2-5 years, or 0-1 year before and after the index date). The 
period ≤1 year before ALS diagnosis might be representative of a time period of symptoms onset and 
clinical diagnostic workup.  
 
To assess the potential influence of age and sex on the studied associations, we separately analyzed men and 
women and individuals at age ≤ 55 and at age ≥ 56. Because familial ALS cases might have different 
association with other neurodegenerative diseases, compared to sporadic ALS cases, we separately analyzed 
ALS cases with a family history. By cross-linking the nested case-control study I to the Multi-Generation 
Register, we identified grandparents, parents, uncles/aunts, full and half siblings, children, nephews/nieces, 
as well as grandchildren of ALS cases and their corresponding controls. We then linked these relatives to the 
Patient Register to obtain ALS diagnosis among them and defined a family history of ALS as having at least 
one of these relatives diagnosed with ALS until the end of 2013.  
 
To investigate if misdiagnosis of neurodegenerative diseases might explain some of the associations 
between other neurodegenerative diseases and ALS, we conducted an additional analysis by restricting the 
definition of ALS and other neurodegenerative diseases to patients with at least two hospital visits 
concerning respective diseases. Given the established ALS/FTD overlap 
17
, we additionally assessed the risk 
of other neurodegenerative diseases among ALS patients after excluding FTD from the definition of 
neurodegenerative diseases. Finally, as depression, neurotic disorders, and stress-related disorders might 
represent collectively the psychological burden of ALS symptoms and diagnosis on ALS patients and their 
families, we analyzed the risk of having depression, neurotic disorders, or stress-related disorders before and 
after ALS diagnosis. 
 
  
 
 
 
We considered statistically significant associations with a two-sided p-value ≤0.05. We performed analyses 
using Stata software, version 14 (StataCorp. 2015, College Station, TX: StataCorp LP). 
Standard Protocol Approvals, Registrations, and Patient Consents 
The Regional Ethical Review Board in Stockholm, Sweden, approved this study. 
Results 
Table 1 shows the sex and age distributions of ALS cases, their controls, and the relatives of both groups. 
The mean age at diagnosis of ALS patients was 60 years (standard deviation=11.30).  
 
Both before and after the index date, we found higher risks for all neurodegenerative diseases studied and 
for depression, neurotic disorders, and drug abuse/dependence among ALS patients, compared to controls 
(Table 2). The associations were strongest for FTD, followed by PD, other or unspecific dementia, and AD. 
Because the proportional hazards assumption was violated after age 68 in the analyses of any 
neurodegenerative disease and other or unspecific dementia, we restricted these analyses to attained age <69 
years and found largely similar results (Table e-2).  
 
Overall, parents, siblings, and children of ALS patients had higher risk of neurodegenerative diseases, both 
before and after the index date, compared to relatives of ALS-free individuals, although the associations 
were only statistically significant for siblings (Table 3). Children of ALS cases had higher risks of 
psychiatric disorders both before and after the index date, compared to children of the controls.  
 
The associations of FTD, AD, other or unspecific dementia, PD, depression, neurotic disorders, and drug 
abuse/dependence with the subsequent ALS risk appeared to be strongest during the year before ALS 
diagnosis, although we also noted positive associations during 2-5 years before diagnosis (Table 4). We 
  
 
 
 
observed further positive associations for schizophrenia and stress-related disorders during the year before 
ALS diagnosis. We noted similar patterns for the associations of ALS with the subsequent risks of 
neurodegenerative or psychiatric diseases, with the strongest association during the first year after diagnosis, 
followed by 2-5 years after diagnosis (Table 4). ALS patients had also an increased risk of stress-related 
disorders after diagnosis, especially during the first year. A clear temporal pattern was however not 
identified for the analyses of the relatives (Table e-3).  
 
All results of the main analyses appeared comparable between males and females (Tables e-4-5) and 
between individuals younger or older than 55 years (Tables e-6-7). We identified a total of 173 ALS patients 
with a family history of ALS (3.9%); separate analysis of these familial ALS cases generally provided 
similar results as in the main analyses (Table e-8).  
 
Among the 3,648 cases of ALS in our study, 3,048 had at least two hospital records concerning ALS, and 
among the 600 cases with only one record, 246 had ALS as a cause of death in the Causes of Death Register. 
Restricting the definition of ALS and other neurodegenerative diseases to patients with at least two hospital 
visits concerning respective diseases slightly attenuated the associations between other neurodegenerative 
diseases and ALS both prior (OR=2.02, 95% CI=1.48-2.77) and after (HR=3.27, 95% CI=2.14-5.00) ALS 
diagnosis. Excluding FTD from the definition of neurodegenerative diseases attenuated also slightly the 
associations of ALS with other neurodegenerative diseases in the overall analyses (prior to index date, 
OR=3.34, 95% CI=2.68-4.16; after index date, HR=3.88, 95% CI=2.87-5.26) and the temporal pattern 
analyses (Table e-9).  
 
The risk of having depression, neurotic disorders, or stress-related disorders was significantly higher among 
ALS patients, compared to controls, both before (OR=1.46, 95% CI=1.28-1.66) and after (HR=3.13, 95% 
  
 
 
 
CI=2.50-3.92) ALS diagnosis. The risk increase peaked during the year before (OR=4.87, 95% CI=3.58-
6.62) and the year after (HR=5.52, 95% CI=3.93-7.76) ALS diagnosis.  
Discussion 
Using a nationwide population-based study sample, we found that ALS patients had higher risks of 
neurodegenerative and psychiatric diseases, both before and after diagnosis. Parents, siblings, and children 
of ALS patients tended to have increased risk of neurodegenerative diseases, whereas only children of ALS 
patients had increased risk of psychiatric disorders.  
 
Although previous studies reported increased risks of dementia and PD after ALS diagnosis 
3, 4
, our study is 
the first to demonstrate the temporal pattern of the increased risks from years before until years after ALS 
diagnosis. We further showed that parents, siblings and children of ALS patients tended also to have 
increased risks of other neurodegenerative diseases, corroborating findings of a recent study in Ireland 
6
. Our 
results lend therefore further support to the hypothesis that shared etiologies or disease mechanisms might 
underlie different neurodegenerative diseases 
6, 8, 9
. Such mechanisms might include shared genetic risk 
factors 
1, 18
,  leading for example to accumulation of protein aggregates in the brain, a common pathological 
finding from different neurodegenerative diseases 
19
. Non-genetic risk factors such as exposure to 
agrochemicals and previous head trauma have also been linked to different neurodegenerative diseases 
20
. 
 
The stronger associations with neurodegenerative diseases noted during the five years before and after ALS 
diagnosis were not reported previously and might be due to different reasons. Misdiagnosis between ALS 
and other neurodegenerative diseases could contribute partially to the increased risk of other 
neurodegenerative diseases among ALS patients. The diagnosis of ALS in the Patient Register appears to 
have high accuracy because a validation study of 280 patients in Stockholm showed a positive predictive 
value of 91% for medical records-based ALS diagnosis 
21
. Restricting the definition of ALS and other 
  
 
 
 
neurodegenerative diseases to patients with at least two hospital visits concerning respective diseases 
attenuated slightly, but did not diminish the results, arguing against misdiagnosis as the pure explanation for 
the observed associations. Furthermore, ALS patients might have been more closely surveyed and more 
likely to receive a diagnosis of another neurodegenerative disease, compared to ALS-free individuals, 
leading to a higher-than-expected risk of other neurodegenerative diseases. It is however also possible that 
some symptoms of other neurodegenerative diseases become under-detected because of the predominant 
ALS symptoms.  
 
We found an increased risk of psychiatric disorders among ALS patients both before and after diagnosis. 
The increased risk of depression is in line with previous reports 
11, 12
. The increased risks of neurotic 
disorders and stress-related disorders are not surprising, because depression, neurotic disorders, and stress-
related disorders are highly correlated clinically 
22
.  
 
The stronger associations with psychiatric disorders noted during the five years before and after ALS 
diagnosis might be due to both non-motor symptoms of ALS and severe stress response toward these 
symptoms and the final diagnosis. Non-motor symptoms of ALS including cognitive impairment are 
increasingly recognized 
23
 and may mimic psychiatric symptoms 
24
. The increased risk of depression might 
partially represent increased prevalence of cognitive impairment among ALS patients. The increased risks of 
depression, neurotic disorders, and stress-related disorders, peaking during the year before and after ALS 
diagnosis, might on the other hand collectively suggest a reactive nature of these psychiatric disorders, 
potentially due to the emotional burden of ALS symptoms and diagnosis.  
 
In line with a previous study that identified an association of schizophrenia with subsequent ALS 
11
, we 
noted an increased risk of schizophrenia during the five years before ALS diagnosis although the association 
  
 
 
 
was only statistically significant during the year before diagnosis. A recent GWAS study also suggested a 
genetic overlap between ALS and schizophrenia 
25
. 
 
In contrast to previous studies 
26-29
, we did not find an association between alcohol abuse/dependence and a 
lower ALS risk. Lack of adjustment for smoking and total energy intake in the present study might partially 
explain these conflicting results. In accord with the previously suggested association between use of opioids 
and ALS 
30
, our study reports a higher risk of drug abuse or dependence (including medicines, cocaine, 
caffeine, opioids, and cannabis) among ALS patients, both before and after ALS diagnosis. While drug 
abuse/dependence might be partially secondary to depression and stress-related disorders 
31-33
, these 
associations diminished but not disappeared after excluding individuals with concurrent drug 
abuse/dependence, depression, or stress-related disorders (data not shown).  
 
We observed an increased risk of psychiatric disorders among children, but not siblings or parents, of ALS 
patients. The vast majority of children of ALS patients that received a psychiatric diagnosis (N=742, 81%) 
received a diagnosis of depression, neurotic disorders, or stress-related disorders, suggesting that 
psychological distress was likely the primary reason for such increased risk. This is possibly explained by 
the fact that children are more involved in caring of ALS patients compared to other relatives 
34
. 
 
Main strengths of our study are the large sample size and the population-based design. The long-term study 
period and the complete follow-up, the prospectively collected information, as well as the ability to 
objectively identify family members and their disease history, represent other main strengths.  
 
We lacked however information on the genetic and clinical characteristics of ALS patients, and were 
therefore unable to separately analyze different subtypes of ALS. Although the completeness of ALS 
diagnosis is presumably high in the Swedish Patient Register because all ALS patients are diagnosed by a 
  
 
 
 
specialist, we might have underestimated the prevalence of some neurodegenerative and psychiatric diseases 
because healthcare provided by general practitioners is not included in the register. The 1% prevalence of 
FTD among the ALS patients might reflect a lack of FTD detection 
35
. Some of the FTD patients might have 
been misclassified as other dementia, partially accounting for the increased risk of other dementia among 
ALS patients. Because the vast majority of children of ALS patients were younger than 60 years of age, risk 
of neurodegenerative diseases at older ages of children needs to be further assessed. Although the clear 
temporal pattern before and after ALS diagnosis argues against confounding as an important explanation for 
the noted associations, residual confounding remains a possibility. Finally, whether or not these findings are 
generalizable to other populations needs to be tested in further studies. 
 
In summary, we found that ALS patients and their first-degree relatives had increased risks of 
neurodegenerative diseases before and after diagnosis, lending further support to a common 
etiopathogenesis for different neurodegenerative diseases. The increased risk of psychiatric disorders among 
ALS patients and their children might be attributable to both the non-motor symptoms of ALS and severe 
stress response to the progressive symptoms and diagnosis of a fatal disease.  
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Table 1. Characteristics of patients with amyotrophic lateral sclerosis (ALS), their matched ALS-free controls, and the respective relatives of both groups 
  N (%) 
 
ALS patients 
ALS-free 
Controls 
Parents of Parents of Siblings of Siblings of Half-siblings Half-siblings Children of  Children of 
  ALS patients controls ALS patients controls 
of ALS 
patients 
of controls ALS patients controls 
Total 3,648 36,480 6,523 65,793 5,593 54,987 662 7,050 6,982 70,964 
Sex 
          
  Male 2,185 (59.90) 21,850 (59.90) 3,167 (48.55) 32,130 (48.83) 2,918 (52.17) 28,310 (51.48) 366 (55.29) 3,601 (51.08) 3,561 (51.00) 36,437 (51.35) 
  Female 1,463 (40.10) 14,630 (40.10) 3,356 (51.45) 33,663 (51.17) 2,675 (47.83) 26,677 (48.52) 296 (44.71) 3,449 (48.92) 3,421 (49.00) 34,527 (48.65) 
Age at Index Date  
          
  ≤ 60 years 1,575 (43.17) 15,750 (43.17) 197 (3.02) 1,820 (2.77) 3,069 (54.87) 30,173 (54.87) 526 (79.46) 5,563 (78.91) 6,980 (99.97) 70,933 (99.96) 
  61-65 years 750 (20.56) 7,500 (20.56) 125 (1.92) 1,328 (2.02) 1,105 (19.76) 10,430 (18.97) 69 (10.42) 714 (10.13) 2 (0.03) 31 (0.04) 
  66-70 years 694 (19.02) 6,940 (19.02) 208 (3.19) 1,970 (2.99) 838 (14.98) 8,200 (14.91) 37 (5.59) 475 (6.74) 0 (0.00) 0 (0.00) 
  71-75 years 441 (12.09) 4,410 (12.09) 302 (4.63) 3,138 (4.77) 453 (8.10) 4,663 (8.48) 23 (3.47) 229 (3.25) 0 (0.00) 0 (0.00) 
  ≥ 76 years 188 (5.15) 1,880 (5.15) 5,691 (87.25) 57,537 (87.45) 128 (2.29) 1,521 (2.77) 7 (1.06) 69 (0.98) 0 (0.00) 0 (0.00) 
 
 
 
 
  
 
 
 
Table 2.  Adjusted associations for age, sex, and county of birth among patients with amyotrophic lateral sclerosis (ALS) and their matched ALS-free controls show a 
higher-than-expected occurrence of neurodegenerative and psychiatric diseases among ALS patients, both before (odds ratios) and after (hazard ratios) ALS diagnosis 
  Prior to Index Date   After Index Date  
 
ALS ALS-free 
  
ALS ALS-free 
 
 
Patients Controls OR (95% CI)^ 
 
Patients Controls HR (95% CI)^ 
  N (%) N (%)     N (%) N (%)   
Any neurodegenerative or psychiatric disease 479 (13.13) 3,370 (9.24) 1.49 (1.35-1.66)   218 (6.88) 2,138 (6.46) 2.90 (2.46-3.43) 
Neurodegenerative diseases* 119 (3.26) 353 (0.97) 3.58 (2.89-4.44)   77 (2.43) 663 (2.00) 3.95 (2.92-5.34) 
    Frontotemporal dementia 17 (0.47) 9 (0.02) 18.9 (8.4-42.4) 
 
15 (0.47) 14 (0.04) 115.6 (15.1-887.0) 
    Alzheimer's disease 23 (0.63) 109 (0.30) 2.1 (1.4-3.4) 
 
10 (0.32) 222 (0.67) 1.9 (1.0-3.7) 
    Other or unspecific dementia 40 (1.10) 130 (0.36) 3.2 (2.2-4.6) 
 
48 (1.51) 317 (0.96) 4.6 (3.1-7.0) 
    Parkinson's disease 57 (1.56) 152 (0.42) 3.85 (2.83-5.24) 
 
25 (0.79) 209 (0.63) 4.7 (2.8-7.8) 
Psychiatric disorders ** 382 (10.47) 3,114 (8.54) 1.26 (1.12-1.41)   150 (4.73) 1,595 (4.82) 2.52 (2.07-3.07) 
    Schizophrenia 22 (0.60) 226 (0.62) 1.0 (0.6-1.5) 
 
1 (0.03) 20 (0.06) 1.7 (0.2-14.1) 
    Bipolar disorder 23 (0.63) 193 (0.53) 1.2 (0.8-1.8) 
 
3 (0.09) 55 (0.17) 1.4 (0.4-4.8) 
    Depression 177 (4.85) 1,197 (3.28) 1.51 (1.28-1.77) 
 
60 (1.89) 634 (1.91) 2.78 (2.05-3.79) 
    Neurotic disorders 136 (3.73) 906 (2.48) 1.53 (1.27-1.84) 
 
58 (1.83) 466 (1.41) 3.07 (2.23-4.24) 
    Stress-related disorders 54 (1.48) 462 (1.27) 1.17 (0.88-1.56) 
 
23 (0.73) 166 (0.50) 2.9 (1.7-5.0) 
    Alcohol abuse/dependence 104 (2.85) 1,125 (3.08) 0.92 (0.75-1.13) 
 
14 (0.44) 390 (1.18) 1.0 (0.5-1.7) 
    Drug abuse/dependence 60 (1.64) 337 (0.92) 1.80 (1.36-2.38)   20 (0.63) 290 (0.88) 2.0 (1.2-3.4) 
* Including frontotemporal dementia, Alzheimer's disease, other or unspecific dementia, and Parkinson's disease 
** Including schizophrenia, bipolar disorder, depression, neurotic disorder, stress-related disorders,  alcohol abuse/dependence, and drug abuse/dependence 
^ OR: odds ratio; HR: hazard ratio; CI: confidence interval; Adjusted for age, sex, and county of birth  
 
 
  
 
 
 
Table 3. Adjusted associations for age, sex, and county of birth among relatives of amyotrophic lateral sclerosis (ALS) patients and their matched ALS-free 
controls show a higher-than-expected occurrence of neurodegenerative diseases among siblings of ALS patients and of psychiatric disorders among children of 
ALS patients, both before (odds ratios) and after (hazard ratios) ALS diagnosis 
  Prior to Index Date 
 
After Index Date 
 
Relatives of Relatives of 
OR (95% CI)^  
Relatives of Relatives of 
HR (95% CI)^ 
 
ALS Patients 
ALS-free 
Controls 
 
ALS Patients ALS-free Controls 
  N (%) N (%) 
 
N (%) N (%) 
Any neurodegenerative or psychiatric disease 
   
 
 
  
 
    Parents 166 (9.08) 1,871 (9.61) 1.01 (0.82-1.22) 
 
180 (10.82) 2,074 (11.79) 1.06 (0.86-1.30) 
    Siblings 451 (9.09) 4,417 (8.99) 1.05 (0.94-1.17) 
 
305 (6.76) 2,666 (5.97) 1.25 (1.08-1.45) 
    Half-siblings 58 (9.83) 739 (11.75) 0.66 (0.42-1.07) 
 
39 (7.33) 410 (7.38) 1.2 (0.6-2.5) 
    Children 459 (7.03) 4,207 (6.31) 1.11 (1.01-1.23) 
 
418 (6.89) 3,736 (5.98) 1.11 (1.00-1.25) 
Neurodegenerative diseases* 
   
 
   
    Parents 73 (3.99) 786 (4.04) 1.13 (0.83-1.52) 
 
132 (7.94) 1,456 (8.27) 1.17 (0.91-1.50) 
    Siblings 48 (0.97) 373 (0.76) 1.41 (1.02-1.96) 
 
93 (2.06) 605 (1.35) 1.76 (1.31-2.36) 
    Half-siblings 3 (0.51) 14 (0.22) n/a 
 
3 (0.56) 21 (0.38) n/a 
    Children 2 (0.03) 14 (0.02) 1.9 (0.4-8.6) 
 
3 (0.05) 32 (0.05) 1.0 (0.3-3.7) 
Psychiatric disorders ** 
   
 
   
    Parents 109 (5.96) 1,237 (6.35) 0.94 (0.74-1.18) 
 
59 (3.55) 771 (4.38) 0.82 (0.58-1.16) 
    Siblings 420 (8.47) 4,151 (8.45) 1.04 (0.93-1.16) 
 
225 (4.99) 2,175 (4.87) 1.12 (0.95-1.33) 
    Half-siblings 55 (9.32) 728 (11.57) 0.69 (0.43-1.12) 
 
36 (6.77) 395 (7.11) 1.2 (0.6-2.5) 
    Children 457 (7.00) 4,199 (6.30) 1.11 (1.01-1.23)   416 (6.85) 3,713 (5.94) 1.11 (1.00-1.25) 
* Including frontotemporal dementia, Alzheimer's disease, other or unspecific dementia, and Parkinson's disease 
** Including schizophrenia, bipolar disorder, depression, neurotic disorder, stress-related disorders,  alcohol abuse/dependence, and drug abuse/dependence 
^ OR: odds ratio; HR: hazard ratio; CI: confidence interval; Adjusted for age, sex, and county of birth of the relatives as well as of the proband individuals 
 
 
  
 
 
 
 
Table 4. Adjusted associations for age, sex, and county of birth among patients with amyotrophic lateral sclerosis (ALS) and their matched ALS-free controls show a higher-than-expected 
occurrence of neurodegenerative and psychiatric diseases during the five years before (odds ratios) until the five years after (hazard ratios) ALS diagnosis 
 
Prior to Index Date; OR (95% CI)^   After Index Date; HR (95% CI)^ 
  ≥ 6 years 2-5 years 0-1 year  
 
0-1 year  2-5 years ≥ 6 years 
Any neurodegenerative or psychiatric disease 1.09 (0.95-1.25) 1.56 (1.27-1.91) 5.48 (4.37-6.87) 
 
5.02 (3.91-6.45) 2.31 (1.75-3.06) 1.30 (0.83-2.05) 
Neurodegenerative diseases* 1.61 (0.96-2.69) 2.50 (1.76-3.55) 9.25 (6.54-13.08) 
 
10.92 (6.73-17.71) 2.47 (1.44-4.24) 1.29 (0.58-2.86) 
    Frontotemporal dementia n/a 12.5 (3.4-46.6) 40.0 (11.3-141.8) 
 
n/a 17.8 (1.6-198.2) n/a 
    Alzheimer's disease 0.9 (0.2-3.7) 1.3 (0.6-2.8) 4.7 (2.5-9.0) 
 
5.4 (1.8-16.5) 1.5 (0.5-4.3) 0.6 (0.1-4.2) 
    Other or unspecific dementia 1.3 (0.5-3.8) 1.0 (0.4-2.1) 12.1 (7.0-20.7) 
 
9.4 (4.9-17.9) 3.6 (1.7-7.6) 1.9 (0.7-4.9) 
    Parkinson's disease 2.1 (1.1-3.9) 3.5 (2.2-5.6) 9.5 (5.2-17.2) 
 
16.9 (6.7-42.5) 3.6 (1.7-7.9) 0.6 (0.1-4.5) 
Psychiatric disorders** 1.05 (0.91-1.21) 1.31 (1.04-1.65) 3.67 (2.76-4.88) 
 
3.89 (2.90-5.24) 2.13 (1.54-2.93) 1.36 (0.82-2.23) 
    Schizophrenia 0.8 (0.5-1.3) 1.4 (0.4-4.8) 5.0 (1.2-20.1) 
 
n/a 10 (0.6-159.9) n/a 
    Bipolar disorder 1.1 (0.6-1.9) 1.2 (0.5-3.0) 2.1 (0.6-7.5) 
 
5.8 (1.0-35.0) n/a 1.3 (0.2-11.1) 
    Depression 1.1 (0.9-1.3) 1.7 (1.3-2.3) 4.8 (3.3-7.0) 
 
5.6 (3.4-9.2) 2.2 (1.3-3.8) 1.5 (0.7-3.0) 
    Neurotic disorders 1.3 (1.1-1.7) 1.2 (0.8-1.7) 4.8 (3.0-7.5) 
 
4.8 (2.9-7.9) 2.6 (1.6-4.4) 1.5 (0.7-3.4) 
    Stress-related disorders 1.1 (0.8-1.6) 0.9 (0.4-1.7) 2.6 (1.3-5.5) 
 
5.5 (2.3-13.4) 2.9 (1.2-6.9) 1.3 (0.4-4.6) 
    Alcohol abuse/dependence 1.0 (0.8-1.2) 0.8 (0.5-1.3) 0.2 (0.0-1.5) 
 
1.2 (0.4-3.4) 1.0 (0.4-2.3) 0.7 (0.2-2.4) 
    Drug abuse/dependence 1.9 (1.3-2.7) 1.2 (0.7-2.2) 2.8 (1.5-5.4)   3.1 (1.4-6.6) 1.9 (0.8-4.7) 0.9 (0.2-4.0) 
* Including frontotemporal dementia, Alzheimer's disease, other or unspecific dementia, and Parkinson's disease 
** Including schizophrenia, bipolar disorder, depression, neurotic disorder, stress-related disorders,  alcohol abuse/dependence, and drug abuse/dependence 
^ OR: odds ratio; HR: hazard ratio; CI: confidence interval; Adjusted for age, sex, and county of birth 
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Supplementary Table e-1 
International Classification of Diseases (ICD) codes used to identify amyotrophic lateral sclerosis (ALS), neurodegenerative diseases, and psychiatric disorders in the Swedish Patient Register 
ICD-8  1969-1986 
 
ICD-9 1987-1996 
 
ICD-10 1997-2013 
ALS 
348.00 Amyotrophic lateral sclerosis 
 
335.C Amyotrophic lateral sclerosis 
 
G12.2 Motor neuron disease 
Frontotemporal dementia 
290.11 Pick’s disease  331.B Pick’s disease  F02.0 Dementia in Pick’s disease 
      G31.0 Pick’s disease 
Alzheimer's disease 
290.10 Alzheimer's disease 
 
290.A
a 
Senile dementia 
 
F00 Dementia in Alzheimer's disease 
   
290.B
a 
Pre-senile dementia 
 
G30 Alzheimer's disease 
   
331.A Alzheimer's disease 
   
Other or unspecific dementia 
290
b 
Senile and pre-senile dementia  290.A Senile dementia  F01 Vascular dementia 
293.0 Psychosis with arteriosclerosis  290.B Pre-senile dementia  F02
c 
Dementia in other diseases classified elsewhere 
293.1 
Psychosis with other cerebrovascular 
condition 
 290.E Vascular dementia  F03 Unspecified dementia 
   290.W 
Other specified senile psychotic 
conditions 
 F05.1 Delirium superimposed on dementia 
   290.X 
Unspecified senile psychotic 
condition 
 G31.1 Senile degeneration of brain 
   294.B 
Dementia in conditions classified 
elsewhere 
 G31.8A
d 
Lewy body disease 
   331.C Senile degeneration of brain    
   331.X Unspecified cerebral degeneration    
Parkinsonian disorders 
342.00 Parkinson's disease 
 
332.A Parkinson's disease 
 
F02.3
d 
Dementia in Parkinson's disease 
342.08 Other defined parkinsonism 
 
333.A Other degenerative diseases of the 
 
G20 Parkinson's disease 
2 
 
basal ganglia 
342.09 Unspecified parkinsonism 
    
G21.4 Vascular parkinsonism 
      
G21.8 Other defined secondary parkinsonism 
      
G21.9 Unspecified secondary parkinsonism 
      
G23.1 Progressive supranuclear ophthalmoplegia 
      
G23.2 Striatonigral degeneration 
      
G23.9 Unspecified degenerative disease of basal ganglia 
      
G25.9 Unspecified extrapyramidal and movement disorder 
            G31.8A
d 
Lewy body disease 
Schizophrenia 
295 Schizophrenia 
 
295 Schizophrenia 
 
F20 Schizophrenia 
Bipolar disorder 
296.1 
Affective psychosis manic-depressive, 
manic type  
296.A Unipolar-Manic affective psychosis 
 
F30 Manic episode 
        
296.3 
Affective psychosis manic-depressive, 
circular type  
296.C 
Bipolar affective psychosis, manic 
phase  
F31 Bipolar disorder 
296.8 
Affective psychosis manic-depressive, 
other specified  
296.D 
Bipolar affective psychosis, 
melancholic phase    
   
296.E 
Bipolar affective psychosis, mild 
form    
   
296.W Other specified affective psychosis 
   
Depression 
300.4 Depressive neurosis 
 
300.E Depressive neurosis 
 
F32
e 
Depressive episode 
   
311 Depression not otherwise specified 
 
F33
f
  Recurrent depressive disorders 
      
F34 Chronic mood disorder 
      
F38 Other mood disorders 
      
F39 Unspecified mood disorder 
3 
 
Neurotic disorders 
300.1 Anxiety disorder 
 
300.A Anxiety disorder 
 
F40 Phobic disorder 
300.2 Phobic disorder 
 
300.B Hysteria 
 
F41 Other anxiety disorders 
300.3 Obsessive compulsive disorder 
 
300.C Phobic disorder 
 
F42 Obsessive compulsive disorder 
300.5 Neurasthenia 
 
300.D Obsessive compulsive 
 
F44 Dissociative syndrome 
300.6 Depersonalization disorder 
 
300.F Neurasthenia 
 
F45 Somatoform disorder 
300.7 Hypochondria 
 
300.G Depersonalization disorder 
 
F48 Other neurotic disorders 
300.8 Other specified neurotic disorder 
 
300.H Hypochondria 
   
300.9 Not otherwise specified 
 
300.W Other specified neurotic disorder 
   
   
300.X Unspecified 
   
Stress-related disorders 
307 Transient situational disturbances 
 
308 Acute reaction to stress 
 
F43 Adjustment disorder and reaction to severe stress 
   
309 Adjustment disorder 
   
Alcohol abuse/dependence 
303 Alcoholism 
 
303 Alcoholism 
 
F10
g 
Mental and behavioral disorders caused by alcohol 
   
305.A Non-dependent alcohol abuse 
   
Drug abuse/dependence 
304 Drug addiction, abuse of drugs 
 
304 Drug addiction 
 
F11
 
Mental and behavioral disorders due to use of 
opioids 
   
305.X Abuse of drugs and medicines 
 
F12 Mental and behavioral disorders caused by cannabis 
      
F13 
Mental and behavioral disorders due to use of 
sedatives and hypnotics 
      
F14 
Mental and behavioral disorders due to use of 
cocaine 
      
F15 
Mental and behavioral disorders due to use of other 
stimulants, including caffeine 
      
F16 
Mental and behavioral disorders due to use of 
hallucinogens 
4 
 
      
F17 
Mental and behavioral disorders due to use of 
tobacco 
      
F18 
Mental and behavioral disorders due to use of 
volatile solvents 
      
F19 
Mental and behavioral disorders due to multiple drug 
use and use of other psychoactive substances 
a 
If found as primary diagnosis 
b 
Except 290.10 (Alzheimer’s disease) and 290.11 (Pick’s disease) 
c 
Except F02.0 (Dementia in Pick’s disease) 
d 
ICD-10 codes considered both dementia and parkinsonian disorder diagnoses  
e 
Except F32.2 (depressive psychosis) 
f
 Except F33.3 (depressive psychosis) 
g 
Except F10.5 (psychotic state) 
5 
 
Supplementary Table e-2 
Adjusted associations for age, sex, and county of birth among 
patients with amyotrophic lateral sclerosis (ALS) and their matched 
ALS-free controls show a higher-than-expected occurrence of 
neurodegenerative and psychiatric diseases after ALS diagnosis 
(hazard ratios); follow-up stopped at 69 years 
  After Index Date 
 
 
 HR (95%CI)* 
Any neurodegenerative disease 8.01 (4.97-12.92) 
Other or unspecific dementia 13.66 (6.38-29.24) 
*HR: hazard ratio; CI: confidence interval; Adjusted for age, sex, 
and county of birth  
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Supplementary Table e-3 
Adjusted associations for age, sex, and county of birth among relatives of patients with amyotrophic lateral sclerosis (ALS) and relatives of their matched ALS-free 
controls do not show clear temporal pattern in the associations of ALS with  neurodegenerative and psychiatric diseases 
 
Prior to Index Date; OR (95% CI)^ 
 
After Index Date; HR (95% CI)^ 
 
≥ 6 years 2-5 years 0-1 year 
 
0-1 year 2-5 years ≥ 6 years 
Any neurodegenerative or psychiatric disease 
       
Parents 0.88 (0.68-1.15) 1.08 (0.79-1.48) 1.3 (0.8-2.2) 
 
0.6 (0.2-1.7) 1.21 (0.81-1.81) 0.97 (0.69-1.35) 
Siblings 1.02 (0.90-1.16) 1.01 (0.81-1.25) 1.5 (1.0-2.1) 
 
1.0 (0.5-1.9) 1.25 (0.95-1.65) 1.29 (1.05-1.58) 
Half-siblings 0.8 (0.5-1.3) 0.5 (0.2-1.3) 0.2 (0.1-1.8) 
 
n/a 0.2 (0.1-1.5) 2.3 (0.7-8.1) 
Children 1.07 (0.93-1.23) 1.25 (1.06-1.47) 0.9 (0.6-1.3) 
 
2.20 (1.32-3.66) 1.07 (0.87-1.32) 0.98 (0.82-1.16) 
Neurodegenerative diseases* 
       
Parents 1.3 (0.7-2.3) 1.0 (0.7-1.5) 1.2 (0.6-2.2) 
 
0.9 (0.2-3.4) 1.27 (0.77-2.10) 0.91 (0.62-1.37) 
Siblings 1.6 (0.9-2.8) 1.2 (0.7-1.9) 1.8 (0.9-3.5) 
 
1.1 (0.1-8.3) 1.5 (0.8-2.6) 2.33 (1.57-3.41) 
Half-siblings n/a n/a n/a 
 
n/a n/a n/a 
Children n/a 3.3 (0.3-33.2) n/a 
 
n/a n/a 1.0 (0.2-5.0) 
Psychiatric disorders** 
       
Parents 0.85 (0.64-1.13) 1.1 (0.7-1.6) 1.3 (0.6-2.9) 
 
0.4 (0.1-1.5) 0.9 (0.4-1.7) 0.9 (0.5-1.5) 
Siblings 1.01 (0.89-1.16) 1.02 (0.81-1.29) 1.4 (0.9-2.0) 
 
1.1 (0.5-2.2) 1.18 (0.87-1.59) 1.04 (0.82-1.32) 
Half-siblings 0.8 (0.5-1.3) 0.5 (0.2-1.5) 0.2 (0.1-1.9) 
 
n/a 0.2 (0.1-1.5) 2.3 (0.7-8.1) 
Children 1.07 (0.93-1.23) 1.24 (1.05-1.47) 0.9 (0.6-1.3) 
 
2.19 (1.31-3.65) 1.08 (0.87-1.33) 0.98 (0.83-1.17) 
* Including frontotemporal dementia, Alzheimer's disease, other or unspecific dementia, and Parkinson's disease 
** Including schizophrenia, bipolar disorder, depression, neurotic disorder, stress-related disorders, alcohol abuse/dependence, and drug abuse/dependence 
^ OR: odds ratio; HR: hazard ratio; CI: confidence interval; Adjusted for age and county of birth, and for age and county of birth of the proband 
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Supplementary Table e-4 
Adjusted associations for age, sex, and county of birth among patients with amyotrophic lateral sclerosis (ALS) and their relatives, compared to ALS-free individuals, show a 
higher-than-expected occurrence of neurodegenerative and psychiatric diseases among ALS patients, of neurodegenerative diseases among siblings of ALS patients, and of 
psychiatric disorders among children of ALS patients, both before (odds ratios) and after (hazard ratios) ALS diagnosis; separate analysis for males 
  Prior to Index Date 
 
After Index Date 
Males 
ALS patients/ ALS-free Controls/ 
OR (95% CI)^ 
 
ALS patients/ ALS-free Controls/ 
HR (95% CI)^ 
Relatives of  Relatives of  
 
Relatives of  Relatives of  
ALS Patients ALS-free Controls 
 
ALS Patients ALS-free Controls 
N (%) N (%) 
 
N (%) N (%) 
Any neurodegenerative or psychiatric  disease 
   
 
   
   Proband 267 (12.22) 2,041 (9.34) 1.36 (1.18-1.56) 
 
130 (6.78) 1,285 (6.49) 2.77 (2.24-3.42) 
   Parents 52 (7.09) 554 (7.55) 1.07 (0.75-1.52) 
 
63 (9.25) 691 (10.18) 0.97 (0.63-1.49) 
   Siblings 226 (8.93) 2.247 (8.98) 1.06 (0.90-1.24) 
 
150 (6.50) 1,363 (5.99) 1.14 (0.90-1.44) 
   Half-siblings 36 (11.11) 368 (11.53) 0.6 (0.3-1.3) 
 
23 (7.99) 199 (7.04) 1.0 (0.3-3.1) 
   Children 211 (6.34) 1,932 (5.64) 1.16 (0.99-1.35) 
 
198 (6.36) 1,637 (5.06) 1.28 (1.07-1.54) 
Neurodegenerative diseases* 
   
 
   
   Proband 62 (2.84) 238 (1.09) 2.74 (2.05-3.67) 
 
51 (2.66) 418 (2.11) 3.46 (2.42-4.94) 
   Parents 17 (2.32) 208 (2.83) 1.0 (0.5-1.8) 
 
45 (6.61) 481 (7.09) 1.1 (0.6-1.9) 
   Siblings 24 (0.95) 179 (0.72) 1.5 (0.9-2.5) 
 
53 (2.30) 316 (1.39) 2.18 (1.36-3.49) 
   Half-siblings 0 (0.00) 7 (0.22) n/a 
 
2 (0.69) 13 (0.46) n/a 
   Children 1 (0.03) 7 (0.02) 1.4 (0.2-12.7) 
 
0 (0.00) 18 (0.06) n/a 
Psychiatric disorders** 
   
 
   
   Proband 216 (9.89)  1,859 (8.51) 1.18 (1.02-1.37) 
 
84 (4.38) 945 (4.77) 2.37 (1.84-3.06) 
   Parents 38 (5.18) 382 (5.20) 1.1 (0.7-1.6) 
 
22 (3.23) 257 (3.79) 0.8 (0.4-1.6) 
   Siblings 210 (8.29) 2,128 (8.51) 1.04 (0.88-1.22) 
 
109 (4.73) 1,097 (4.82) 1.00 (0.76-1.29) 
   Half-siblings 36 (11.11) 362 (11.34) 0.6 (0.3-1.3) 
 
21 (7.29) 189 (6.69) 1.0 (0.3-3.1) 
   Children 210 (6.31) 1,927 (5.62) 1.16 (0.99-1.35)   198 (6.36) 1,625 (5.03) 1.30 (1.08-1.56) 
* Including frontotemporal dementia, Alzheimer's disease, other or unspecific dementia, and Parkinson's disease 
** Including schizophrenia, bipolar disorder, depression, neurotic disorder, stress-related disorders,  alcohol abuse/dependence, and drug abuse/dependence 
^ OR: odds ratio; HR: hazard ratio; CI: confidence interval; Adjusted for age and county of birth, and for age and county of birth of the proband in the analyses of relatives 
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Supplementary Table e-5 
Adjusted associations for age, sex, and county of birth among patients with amyotrophic lateral sclerosis (ALS) and their relatives, compared to ALS-free individuals, show a higher-
than-expected occurrence of neurodegenerative and psychiatric diseases among ALS patients, and of neurodegenerative diseases among siblings of ALS patients, both before 
(odds ratios) and after (hazard ratios) ALS diagnosis; separate analysis for females 
  Prior to Index Date 
 
After Index Date 
Females 
ALS patients/ ALS-free Controls/ 
 
 
ALS patients/ ALS-free Controls/ 
 
Relatives of  Relatives of  
OR (95% CI)^  
Relatives of  Relatives of  
HR (95% CI)^ ALS Patients ALS-free Controls 
 
ALS Patients ALS-free Controls 
N (%) N (%) 
 
N (%) N (%) 
Any neurodegenerative or psychiatric disease 
   
 
   
   Proband 212 (14.49) 1,329 (9.08) 1.70 (1.46-1.99) 
 
88 (7.03) 853 (6.41) 3.16 (2.40-4.15) 
   Parents 114 (10.40) 1,317 (10.86) 1.02 (0.80-1.30) 
 
117 (11.91) 1,383 (12.79) 1.05 (0.80-1.39) 
   Siblings 225 (9.27) 2,170 (9.00) 1.07 (0.91-1.25) 
 
155 (7.04) 1,303 (5.94) 1.29 (1.02-1.62) 
   Half-siblings 22 (8.27) 371 (11.98) 0.5 (0.2-1.1) 
 
18 (6.72) 217 (7.18) 2.5 (0.7-8.8) 
   Children 248 (7.75) 2,275 (7.02) 1.06 (0.91-1.22) 
 
220 (7.45) 2,099 (6.96) 1.00 (0.84-1.19) 
Neurodegenerative diseases* 
          Proband 57 (3.90) 115 (0.79) 5.26 (3.79-7.31) 
 
26 (2.08) 245 (1.84) 5.4 (3.1-9.2) 
   Parents 56 (5.11) 578 (4.77) 1.18 (0.82-1.70) 
 
87 (8.86) 975 (9.02) 1.18 (0.84-1.66) 
   Siblings 24 (0.99) 194 (0.81) 1.5 (0.9-2.4) 
 
40 (1.82) 289 (1.32) 1.6 (1.0-2.6) 
   Half-siblings 3 (1.13) 7 (0.23) n/a 
 
1 (0.37) 9 (0.30) n/a 
   Children 1 (0.03) 7 (0.02) 3.1 (0.3-35.3) 
 
3 (0.10) 14 (0.05) 6.0 (0.9-41.2) 
Psychiatric disorders** 
   
 
   
    Proband 166 (11.35) 1,255 (8.58) 1.37 (1.15-1.62) 
 
66 (5.28) 650 (4.89) 2.76 (2.03-3.76) 
    Parents 71 (6.48) 855 (7.05) 0.94 (0.70-1.26) 
 
37 (3.77) 514 (4.75) 0.8 (0.5-1.3) 
    Siblings 210 (8.65) 2,023 (8.39) 1.06 (0.90-1.25) 
 
116 (5.27) 1,078 (4.92) 1.17 (0.90-1.52) 
    Half-siblings 19 (7.14) 366 (11.81) 0.6 (0.3-1.2) 
 
17 (6.34) 211 (6.98) 2.5 (0.7-8.8) 
    Children 247 (7.71) 2,272 (7.01) 1.05 (0.91-1.22)   218 (7.38) 2,088 (6.93) 0.99 (0.83-1.18) 
* Including frontotemporal dementia, Alzheimer's disease, other or unspecific dementia, and Parkinson's disease 
** Including schizophrenia, bipolar disorder, depression, neurotic disorder, stress-related disorders,  alcohol abuse/dependence, and drug abuse/dependence 
^ OR: odds ratio; HR: hazard ratio; CI: confidence interval; Adjusted for age and county of birth, and for age and county of birth of the proband in the analyses of relatives 
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Supplementary Table e-6 
Adjusted associations for age, sex, and county of birth among patients with amyotrophic lateral sclerosis (ALS) and their relatives, compared to ALS-free individuals, show a higher-
than-expected occurrence of neurodegenerative and psychiatric diseases among ALS patients, and of psychiatric disorders among children of ALS patients, both before (odds ratios) 
and after (hazard ratios) ALS diagnosis; separate analysis for individuals ≤55 years 
  Prior to Index Date 
 
After Index Date 
≤ 55 years at Index date 
ALS patients/ ALS-free Controls/ 
OR (95% CI)^  
ALS patients/ ALS-free Controls/ 
HR (95% CI)^ Relatives of  Relatives of  
 
Relatives of  Relatives of  
ALS Patients ALS-free Controls 
 
ALS Patients ALS-free Controlss 
N (%) N (%) 
 
N (%) N (%) 
Any neurodegenerative or psychiatric disease 
   
 
   
   Proband 96 (9.93) 726 (7.51) 1.36 (1.09-1.71) 
 
67 (7.69) 636 (7.11) 2.45 (1.82-3.30) 
   Parents 8 (7.34) 73 (7.14) 0.9 (0.4-2.3) 
 
7 (6.93) 80 (8.42) 0.5 (0.2-1.6) 
   Siblings 141 (7.44) 1,426 (7.52) 0.95 (0.77-1.16) 
 
139 (7.92) 1,252 (7.14) 1.18 (0.95-1.46) 
   Half-siblings 37 (9.44) 485 (11.47) 0.5 (0.3-1.0) 
 
30 (8.45) 334 (8.92) 1.0 (0.4-2.1) 
   Children 455 (7.02) 4,137 (6.25) 1.12 (1.01-1.25) 
 
418 (6.94) 3,730 (6.01) 1.11 (0.99-1.25) 
Neurodegenerative diseases* 
          Proband 19 (1.96) 7 (0.07) 27.1 (11.4-64.6) 
 
15 (1.72) 48 (0.54) 6.7 (2.8-15.9) 
   Parents 0 (0.00) 0 (0.00) n/a 
 
1 (0.99) 6 (0.63) 3.3 (0.2-45.1) 
   Siblings 2 (0.11) 19 (0.10) 0.9 (0.2-5.1) 
 
16 (0.91) 108 (0.62) 1.8 (0.9-3.5) 
   Half-siblings 0 (0.00) 4 (0.09) n/a 
 
1 (0.28) 9 (0.24) n/a 
   Children 1 (0.02) 12 (0.02) 1.1 (0.1-9.3) 
 
3 (0.05) 32 (0.05) 1.0 (0.3-3.5) 
Psychiatric disorders** 
   
 
   
   Proband 81 (8.38) 722 (7.47) 1.13 (0.89-1.44) 
 
55 (6.31) 600 (6.71) 2.25 (1.64-3.08) 
   Parents 8 (7.34) 73 (7.14) 0.9 (0.4-2.3) 
 
6 (5.94) 78 (8.21) 0.4 (0.1-1.3) 
   Siblings 139 (7.34) 1,413 (7.45) 0.94 (0.76-1.15) 
 
128 (7.30) 1,175 (6.70) 1.12 (0.90-1.40) 
   Half-siblings 37 (9.44) 483 (11.42) 0.5 (0.3-1.0) 
 
29 (8.17) 329 (8.79) 1.0 (0.4-2.1) 
   Children 454 (7.00) 4,130 (6.24) 1.12 (1.01-1.24)  416 (6.90) 3,707 (5.97) 1.11 (0.99-1.25) 
* Including frontotemporal dementia, Alzheimer's disease, other or unspecific dementia, and Parkinson's disease 
** Including schizophrenia, bipolar disorder, depression, neurotic disorder, stress-related disorders,  alcohol abuse/dependence, and drug abuse/dependence 
^ OR: odds ratio; HR: hazard ratio; CI: confidence interval; Adjusted for age and county of birth, and for age and county of birth of the proband in the analyses of relatives 
10 
 
Supplementary Table e-7 
Adjusted associations for age, sex, and county of birth among patients with amyotrophic lateral sclerosis (ALS) and their relatives, compared to ALS-free individuals, show a 
higher than expected occurrence of neurodegenerative and psychiatric diseases among ALS patients, and of neurodegenerative diseases among siblings of ALS patients, both 
before (odds ratios) and after (hazard ratios) ALS diagnosis; separate analyses for individuals ≥56 years 
 
Prior to Index Date 
 
After Index Date 
≥ 56 years at Index date 
ALS patients/ ALS-free Controls/ 
OR (95% CI)^  
ALS patients/ ALS-free Controls/ 
HR (95% CI)^ 
Relatives of  Relatives of  
 
Relatives of  Relatives of  
ALS Patients ALS-free Controls 
 
ALS Patients ALS-free Controls 
N (%) N (%) 
 
N (%) N (%) 
Any neurodegenerative or psychiatric disease 
  
  
   
   Proband 383 (14.29) 2,644 (9.86) 1.53 (1.36-1.72) 
 
151 (6.57) 1,502 (6.22) 3.15 (2.57-3.86) 
   Parents 158 (9.19) 1,798 (9.75) 1.01 (0.82-1.23) 
 
173 (11.08) 1,994 (11.98) 1.10 (0.88-1.3) 
   Siblings 310 (10.11) 2,991 (9.92) 1.06 (0.93-1.21) 
 
166 (6.03) 1,414 (5.21) 1.36 (1.10-1.68) 
   Half-siblings 21 (10.61) 254 (12.32) 0.5 (0.2-1.7) 
 
9 (5.08) 76 (4.21) n/a 
   Children 4 (8.70) 70 (13.73) 1.0 (0.3-3.9) 
 
0 (0.00) 6 (1.36) n/a 
Neurodegenerative diseases* 
          Proband 100 (3.73) 346 (1.29) 3.05 (2.42-3.83) 
 
62 (2.70) 615 (2.54) 3.71 (2.68-5.13) 
   Parents 73 (4.24) 786 (4.26) 1.08 (0.80-1.46) 
 
131 (8.39) 1,450 (8.71) 1.17 (0.91-1.50) 
   Siblings 46 (1.50) 354 (1.17) 1.6 (1.1-2.3) 
 
77 (2.79) 497 (1.83) 1.81 (1.29-2.53) 
   Half-siblings 3 (1.52) 10 (0.49) n/a 
 
2 (1.13) 12 (0.66) n/a 
   Children 1 (2.17) 2 (0.39) n/a 
 
0 (0.00) 0 (0.00) n/a 
Psychiatric disorders** 
   
 
   
   Proband 301 (11.23) 2,392 (8.92) 1.29 (1.14-1.47) 
 
95 (4.13) 995 (4.12) 2.71 (2.10-3.48) 
   Parents 101 (5.87) 1,164 (6.31) 0.95 (0.75-1.21) 
 
53 (3.39) 693 (4.16) 0.89 (0.62-1.28) 
   Siblings 281 (9.17) 2,738 (9.08) 1.05 (0.91-1.21) 
 
97 (3.52) 1,000 (3.68) 1.16 (0.89-1.50) 
   Half-siblings 18 (9.09) 245 (11.89) 0.5 (0.2-1.7) 
 
7 (3.95) 66 (3.65) n/a 
   Children 3 (6.52) 69 (13.53) 0.8 (0.2-3.5)   0 (0.00) 6 (1.36) n/a 
* Including frontotemporal dementia, Alzheimer's disease, other or unspecific dementia, and Parkinson's disease 
** Including schizophrenia, bipolar disorder, depression, neurotic disorder, stress-related disorders,  alcohol abuse/dependence, and drug abuse/dependence 
^ OR: odds ratio; HR: hazard ratio; CI: confidence interval; Adjusted for age and county of birth, and for age and county of birth of the proband in the analyses of relatives 
11 
 
Supplementary Table e-8 
Adjusted associations for age, sex, and county of birth among patients with familial amyotrophic lateral sclerosis (ALS) and their matched 
ALS-free controls show a higher-than-expected occurrence of neurodegenerative and psychiatric diseases among familial ALS patients, 
both before (odds ratios) and after(hazard ratios) ALS diagnosis 
  Prior to Index Date   After Index Date  
 
ALS ALS-free 
  
ALS ALS-free 
 
 
Patients Individuals OR (95% CI)^ 
 
Patients Individuals HR (95% CI)^ 
  N (%) N (%)     N (%) N (%)   
Any neurodegenerative or psychiatric disease 21 (12.14) 153 (8.84) 1.4 (0.9-2.4)   10 (6.58) 113 (7.17) 3.1 (1.3-7.3) 
Neurodegenerative diseases* 5 (2.89) 9 (0.52) 5.9 (1.9-18.0)   2 (1.32) 29 (1.84) 2.2 (0.2-20.1) 
Psychiatric disorders** 17 (9.83) 147 (8.50) 1.2 (0.7-2.0)   8 (5.26) 92 (5.83) 3.1 (1.2-7.9) 
* Including frontotemporal dementia, Alzheimer's disease, other dementia, and Parkinson's disease 
** Including schizophrenia, bipolar disorder, depression, neurotic disorder, stress-related disorders,  alcohol abuse/dependence, and drug 
abuse/dependence 
 
Supplementary Table e-9 
Adjusted associations for age, sex, and county of birth among patients with amyotrophic lateral sclerosis (ALS) and their matched ALS-free controls 
show a higher-than-expected occurrence of neurodegenerative diseases among ALS patients, even after excluding frontotemporal dementia from the 
definition of neurodegenerative diseases 
 
Prior to Index Date; OR (95% CI)^   After Index Date; HR (95% CI)^ 
  ≥ 6 years 2-5 years 0-1 year  
 
0-1 year  2-5 years ≥ 6 years 
Neurodegenerative diseases* 1.60 (0.96-2.69) 2.18 (1.51-3.15) 8.80 (6.20-12.50)   10.04 (6.14-16.44) 2.76 (1.64-5.63) 1.29 (0.58-2.86) 
* Including Alzheimer's disease, other dementia, and Parkinson's disease 
^ Adjusted for age, sex, and county of birth  
 
 
 
 
 
 
